Skip to main content

Pre-bookings open! Windows 10 Lenovo Laptops

FREE SPEAKERS ON PRE - BOOKING
BUY NOW
Windows 10 is Here!
Windows 10 is Here!
Experience It first on Lenovo™ Laptops
There's so much more you can do on a new Windows 10 Lenovo Laptop. It's faster, more responsive and inbuilt with more security features. Plus, with features like Cortana, the personal digital assistant*, your Lenovo Laptop is ready to take your computing experience to a whole new level.
Pre-Book Now
Lenovo™ Z Series Laptops
Rich in multimedia features like Dolby® enhanced audio and a Full HD display, Lenovo™ Z Series Laptops are the experts in entertainment, whenever you need it.
Starting at 54,090
Buy a Lenovo™ Laptop
with Windows 10
Get Lenovo™ Speakers M0520 Absolutely
FREE!
Lenovo™ G Series Laptops
Ultra-reliable and extremely portable, Lenovo™ G Series Laptops are just what you need to manage your day-to-day activities.
Lenovo™ Yoga 500 Laptops
Exceptionally thin and light, intelligent in performance and revolutionary in design – Lenovo™ Yoga 500 Laptops come with four unique modes – Laptop, Tent, Stand and Tablet – to work or play.
Starting at 33,990
Starting at 72,990
PRE-BOOK NOW
To avail the offer, customers must pre-book their purchase.
Unsubscribe from Lenovo e-mails | Privacy Policy
*Cortana available in select markets at launch, experience may vary by region and device.
© 2015 Lenovo, all rights reserved. Lenovo and the Lenovo logo are trademarks of Lenovo in the United States, other countries, or both. Microsoft and Windows are the registered trademarks of Microsoft Corporation. Intel, the Intel logo and Intel Core are the trademarks or registered trademarks of Intel Corporation in the U.S. and/or other countries. Other company, product and service names may be the trademarks or service marks of others. Lenovo reserves the right to correct any inaccuracies, errors, or omissions and to change or update information at any time, without prior notice. All images shown are for illustrative purposes only, and might not resemble the actual product.


Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More